SARS-CoV-2 immunochromatographic IgM/IgG rapid test in pregnancy: A false friend?
Fabre, M. ; Ruiz-Martinez, S. ; Monserrat Cantera, M.E. ; Cortizo Garrido, A. ; Beunza Fabra, Z. ; Peran, M. ; Benito, R. (Universidad de Zaragoza) ; Mateo, P. (Universidad de Zaragoza) ; Paules, C. (Universidad de Zaragoza) ; Oros, D. (Universidad de Zaragoza)
Resumen: Background: An increasing body of evidence has revealed that SARS-CoV-2 infection in pregnant women could increase the risk of adverse maternal and fetal outcomes. Careful monitoring of pregnancies with COVID-19 and measures to prevent neonatal infection are warranted. Therefore, rapid antibody tests have been suggested as an efficient screening tool during pregnancy.
Cases: We analysed the clinical performance during pregnancy of a rapid, lateral-flow immunochromatographic assay for qualitative detection of SARS-CoV-2 IgG/IgM antibodies. We performed a universal screening including 169 patients during their last trimester of pregnancy. We present a series of 14 patients with positive SARS-CoV-2 immunochromatographic assay rapid test result. Immunochromatographic assay results were always confirmed by chemiluminescent microparticle immunoassays for quantitative detection of SARS-CoV-2 IgG and IgM+IgA antibodies as the gold standard. We observed a positive predictive value of 50% and a false positive rate of 50% in pregnant women, involving a significantly lower diagnostic performance than reported in non-pregnant patients.
Discussion: Our data suggest that although immunochromatographic assay rapid tests may be a fast and profitable screening tool for SARS-CoV-2 infection, they may have a high false positive rate and low positive predictive value in pregnant women. Therefore, immunochromatographic assay for qualitative detection of SARS-CoV-2 IgG/IgM antibodies must be verified by other test in pregnant patients.
Idioma: Inglés
DOI: 10.1177/0004563220980495
Año: 2020
Publicado en: ANNALS OF CLINICAL BIOCHEMISTRY 58, 2 (2020), 149-152
ISSN: 0004-5632
Factor impacto JCR: 2.057 (2020)
Categ. JCR: MEDICAL LABORATORY TECHNOLOGY rank: 20 / 29 = 0.69 (2020) - Q3 - T3
Factor impacto SCIMAGO: 0.6 - Medicine (miscellaneous) (Q2) - Clinical Biochemistry (Q2)
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/CM18-00202
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/JR19-00006
Tipo y forma: Article (Published version)
Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)
Área (Departamento): Área Obstetricia y Ginecología (Dpto. Cirugía)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.
Exportado de SIDERAL (2022-06-21-09:40:15)
Visitas y descargas
Cases: We analysed the clinical performance during pregnancy of a rapid, lateral-flow immunochromatographic assay for qualitative detection of SARS-CoV-2 IgG/IgM antibodies. We performed a universal screening including 169 patients during their last trimester of pregnancy. We present a series of 14 patients with positive SARS-CoV-2 immunochromatographic assay rapid test result. Immunochromatographic assay results were always confirmed by chemiluminescent microparticle immunoassays for quantitative detection of SARS-CoV-2 IgG and IgM+IgA antibodies as the gold standard. We observed a positive predictive value of 50% and a false positive rate of 50% in pregnant women, involving a significantly lower diagnostic performance than reported in non-pregnant patients.
Discussion: Our data suggest that although immunochromatographic assay rapid tests may be a fast and profitable screening tool for SARS-CoV-2 infection, they may have a high false positive rate and low positive predictive value in pregnant women. Therefore, immunochromatographic assay for qualitative detection of SARS-CoV-2 IgG/IgM antibodies must be verified by other test in pregnant patients.
Idioma: Inglés
DOI: 10.1177/0004563220980495
Año: 2020
Publicado en: ANNALS OF CLINICAL BIOCHEMISTRY 58, 2 (2020), 149-152
ISSN: 0004-5632
Factor impacto JCR: 2.057 (2020)
Categ. JCR: MEDICAL LABORATORY TECHNOLOGY rank: 20 / 29 = 0.69 (2020) - Q3 - T3
Factor impacto SCIMAGO: 0.6 - Medicine (miscellaneous) (Q2) - Clinical Biochemistry (Q2)
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/CM18-00202
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/JR19-00006
Tipo y forma: Article (Published version)
Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)
Área (Departamento): Área Obstetricia y Ginecología (Dpto. Cirugía)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material. Exportado de SIDERAL (2022-06-21-09:40:15)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles > Artículos por área > Obstetricia y Ginecología
Articles > Artículos por área > Microbiología
Record created 2021-01-15, last modified 2022-06-21